NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric.
HTL0039732 is a novel EP4 antagonist designed by Sosei Heptares with potential to treat a wide range of cancers in combination with other immunotherapies Tokyo, Japan, London and Cambridge, UK, 10 August 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world-leader in GPCR-focused structure-based drug design (SBDD) and development, and Cancer Research UK, the world’s largest independent funder of cancer research, today announce that the first patient has been dosed in a Phase I/IIa
Tokyo, Japan and Cambridge, UK, 4 August 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports.
Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2023 itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Tokyo, Japan and Cambridge, UK, 20 July 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), will hold an investor and press conference on today’s.